Generic drugmaker Lupin has launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States, a product bioequivalent to Bausch & Lomb Inc’s Lotemax Ophthalmic Suspension, 0.5%.
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is used in treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea and superficial punctate keratitis. It is also indicated for the treatment of post-operative inflammation following ocular surgery, Lupin said on Wednesday in a release on the launch.
The product (reference listed drug Lotemax) had estimated annual sales of $55 million in the U.S., it said citing IQVIA MAT May 2025 numbers.
Published – July 16, 2025 09:45 pm IST
